Retatrutide
Clinical TrialsRetatrutide
A triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Investigational compound with some of the most dramatic weight loss data ever seen in clinical trials.
Dose
2mg, 4mg, 8mg, 12mg (escalating)
Route
SubQ injection
Cycle
Typically 24-48 weeks in research protocols, with extensions up to 88 weeks observed
Storage
2°C to 8°C (36°F to 46°F), protected from light
What is Retatrutide?
Retatrutide is an investigational unimolecular agonist of the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple agonist mechanism aims to leverage the complementary effects of these three incretin hormones to promote significant weight loss, improve glycemic control, and potentially offer cardiovascular benefits. Research has shown unprecedented weight reduction outcomes in human trials, making it a prominent compound in the field of obesity and metabolic disease research.
Key Benefits
- Exceptional weight reduction (up to 24% in trials)
- Metabolic improvement
- Appetite suppression
- Potential cardiovascular benefits
Mechanism of Action
- Triple agonist: GLP-1, GIP, and glucagon receptors
- Enhanced fat oxidation via glucagon
- Appetite suppression
- Improves insulin sensitivity
Best For
- Advanced weight management research
- Metabolic health
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
4691.3 g/mol
Length
39 amino acids
Type
Peptide
Amino acid sequence
Y-Q-G-T-F-T-S-D-Y-S-I-A-M-D-K-I-H-Q-Q-D-F-V-N-W-L-L-A-Q-G-G-P-S-S-G-A-P-P-S-K
Amidation at the C-terminus and C20 fatty acid acylation (eicosanedioic acid) at the Lysine residue.
Pharmacokinetics
Time to peak
Approximately 10 hours
Half-life
144 h
Time to clear
Approximately 3-4 weeks
Based on pharmacokinetic data from clinical trials (e.g., NCT04881760)
Research Indications
Obesity and Overweight with Comorbidities
Research indicates substantial and sustained weight loss (up to 24% in trials) in individuals with obesity or overweight, often leading to improvements in weight-related comorbidities.
Appetite Regulation
Mechanism of action through GLP-1, GIP, and glucagon receptor agonism effectively suppresses appetite and reduces caloric intake.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Initial Dose Escalation for Weight Loss | 2mg weekly for 4 weeks, then 4mg weekly for 4 weeks | Once weekly | Subcutaneous |
| Continued Dose Escalation for Optimal Weight Loss | 8mg weekly for 4 weeks, then 12mg weekly | Once weekly | Subcutaneous |
| Long-Term Weight Management and Metabolic Improvement | 12mg weekly | Once weekly | Subcutaneous |
| Monitoring for Gastrointestinal Tolerance | Flexible, based on individual tolerance | Once weekly (with potential temporary dose reduction if severe side effects occur) | Subcutaneous |
| Assessment of Glycemic Control | Escalating doses as per weight loss protocols, up to 12mg weekly | Once weekly | Subcutaneous |
Dose escalation is commonly discussed in research protocols to mitigate gastrointestinal side effects.
Peptide Interactions
- Use Caution
Insulin secretagogues (e.g., sulfonylureas)
May increase the risk of hypoglycemia. Dose adjustment of insulin secretagogues may be necessary.
- Use Caution
Insulin
May increase the risk of hypoglycemia. Close glucose monitoring and potential insulin dose reduction are commonly discussed.
- Monitor Combination
Oral medications (especially those with a narrow therapeutic index)
Retatrutide can slow gastric emptying, potentially affecting the absorption of co-administered oral medications. Monitor for altered efficacy or increased side effects of oral drugs.
- Compatible
Beta-blockers
No significant direct interaction reported, but monitor heart rate as Retatrutide may cause slight increases.
- Monitor Combination
Alcohol
Can exacerbate gastrointestinal side effects and potentially affect blood glucose levels. Moderate consumption is commonly advised in research settings.
How to Reconstitute
- 1Gather necessary supplies: Retatrutide vial, sterile bacteriostatic water for injection (BWFI), sterile syringes with appropriate needles, alcohol wipes.
- 2Clean the rubber stopper of the Retatrutide vial and the BWFI vial with alcohol wipes and allow to air dry.
- 3Draw the appropriate volume of BWFI (e.g., 1mL for a 5mg vial) into a sterile syringe.
- 4Slowly inject the BWFI into the Retatrutide vial, aiming the stream towards the side of the vial to avoid direct impact on the lyophilized powder.
- 5Gently swirl the vial to dissolve the powder. Do not shake vigorously, as this can denature the peptide.
- 6Once fully dissolved, the solution should be clear and colorless. Store according to guidelines.
Aseptically reconstitute with sterile bacteriostatic water for injection (BWFI).
What to Expect
- Weeks 1-4: Initial dose escalation may cause mild gastrointestinal side effects such as nausea or constipation. Appetite suppression and initial weight loss may begin.
- Weeks 5-12: Continued dose escalation, as tolerated. More noticeable reductions in appetite and food intake, leading to steady weight reduction.
- Weeks 13-24: Significant and consistent weight loss observed. Metabolic markers (e.g., glucose, insulin sensitivity) may show improvement.
- Weeks 25-48+: Continued weight loss or maintenance of achieved weight loss. Potential for further metabolic and cardiovascular benefits. Side effects typically decrease in intensity with continued use.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Very Common | Mild-Moderate |
| Vomiting | Common | Mild |
| Decreased appetite | Very Common | Mild |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.